These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32838414)

  • 1. Does Degarelix Hold Potential for the Treatment of Pedophilic Disorder?
    ElSayed M; Gupta R
    JAMA Psychiatry; 2020 Oct; 77(10):1084-1085. PubMed ID: 32838414
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial.
    Landgren V; Malki K; Bottai M; Arver S; Rahm C
    JAMA Psychiatry; 2020 Sep; 77(9):897-905. PubMed ID: 32347899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Degarelix Hold Potential for the Treatment of Pedophilic Disorder?-Reply.
    Rahm C; Landgren V; Arver S
    JAMA Psychiatry; 2020 Oct; 77(10):1085. PubMed ID: 32838416
    [No Abstract]   [Full Text] [Related]  

  • 4. A Randomized Clinical Trial in Patients With a Pedophilic Disorder: A Milestone.
    Briken P
    JAMA Psychiatry; 2020 Sep; 77(9):893-894. PubMed ID: 32347907
    [No Abstract]   [Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
    Sonesson A; Rasmussen BB
    Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
    Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
    Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
    J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.
    Sciarra A; Fasulo A; Ciardi A; Petrangeli E; Gentilucci A; Maggi M; Innocenzi M; Pierella F; Gentile V; Salciccia S; Cattarino S
    Medicine (Baltimore); 2016 Jul; 95(27):e3845. PubMed ID: 27399062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.